Table 1. Characteristics of study population (patients who were vulnerable at baseline, that is at increased risk of an adverse drug event with non-steroidal anti-inflammatory drugs and/or antiplatelet medicinesa) from the two participating general practices
General practice A
(registered patients: = 7944)
General practice B
(registered patients: = 2500)
Total
Vulnerable patientsa, n (%)668 (8.6)202 (8.1)870 (8.9)
Age, mean (SD)74.9 (11.2)73.2 (12.3)74.5 (11.4)
Female, n (%)392 (58.7)96 (47.5)488 (56.1)
Ethnicity, n (%):
 New Zealand European321 (48.1)157 (77.7)478 (54.9)
 Other European253 (37.9)23 (11.4)276 (31.7)
 New Zealand Maori7 (1.0)4 (2.0)11 (1.3)
 Pasifika5 (0.7)1 (0.5)6 (0.7)
 East Asian29 (4.3)6 (3.0)35 (4.0)
 Indian12 (1.8)7 (3.5)19 (2.2)
 Other41 (6.1)4 (2.0)45 (5.2)
Number of long-term medicines, mean (SD)4.07 (1.86)1.35 (0.56)3.44 (2.01)
  • aPatients with one or more risk factor for gastrointestinal, renal, or cardiac adverse effects when prescribed NSAID and/or antiplatelet medicines. SD = standard deviation.